What is the current data on the 2026‑2027 seasonal influenza vaccine?

Current Data on the 2025-26 Flu Vaccine (Note: No 2026-27 Data Available Yet)

The most current official recommendations are for the 2025-26 influenza season, not 2026-27—the 2026-27 vaccine composition and guidelines have not yet been determined. 1

Key Updates for 2025-26 Season

The ACIP issued updated recommendations in 2025 with four major changes from the prior season 1:

1. Universal Vaccination Recommendation Continues

• All persons aged ≥6 months should receive annual influenza vaccination unless contraindicated
• This remains the cornerstone recommendation to reduce morbidity and mortality 1

2. New Thimerosal-Free Requirement

ACIP now recommends that children aged ≤18 years, pregnant women, and all adults receive only single-dose, thimerosal-free formulations 1

• This is a significant policy shift eliminating preservative-containing multi-dose vials for these populations
• Addresses long-standing safety concerns despite lack of evidence for harm

3. Expanded Age Indications

• Flublok (RIV3): Now FDA-approved for ages ≥9 years (previously ≥18 years) 1
• FluMist (LAIV3): FDA-approved for self-administration (ages 18-49) or caregiver administration (ages 2-17) 1

4. Updated Antigenic Composition

• All 2025-26 vaccines are trivalent (IIV3, RIV3, LAIV3) 1
• FDA issued new strain recommendations in March 2025 1

Optimal Timing

Vaccinate in September or October for most patients 1

Avoid July-August vaccination for:

• Adults ≥65 years (highest risk of immunity waning) 1
• Pregnant women in first/second trimester 1

Exception—Vaccinate early (including July-August) for:

• Children requiring 2 doses: Those aged 6 months-8 years who haven't received ≥2 prior doses need their first dose early to complete the series by October 1
• Any patient where later vaccination may not be feasible 1

Emerging 2025-26 Season Data

Interim Vaccine Effectiveness (September 2025-February 2026)

Real-world VE data from the current season shows moderate but meaningful protection 2:

Against outpatient visits:

• Children/adolescents: 38-41% VE
• Adults: 22-34% VE

Against hospitalization:

• Children/adolescents: 41% VE
• Adults: 30% VE

Subtype-specific findings:

• VE against influenza B: 45-71% (children), 63% (adults)
• VE against H3N2: 35-38% (children)
• These estimates are lower than recent seasons but still demonstrate clinically significant protection 2

Why Lower Effectiveness This Season?

H3N2 subclade K emergence: This antigenically advanced variant became dominant in late 2025 3, 4

• Human sera show lower neutralizing titers against subclade K strains 3
• The 2025-26 vaccine does elicit antibodies recognizing these viruses, but with reduced efficiency 4
• Additional mutations in antigenic regions D and E further reduce vaccine-induced immunity 3

Critical Clinical Implications

Despite Lower VE, Vaccination Still Prevents Severe Outcomes

The vaccine continues to reduce mortality and severe disease 5:

• VE against influenza-associated death in children: 80% (95% CI: 75-84%) based on 8 seasons of surveillance data 5
• VE against hospitalization in older adults: 19-43% across multiple seasons 5
• VE against mortality in older adults: 29-66% 5

High-dose vaccine superiority in older adults: RCT data from 2022-2025 seasons showed 43.6% relative VE improvement with high-dose versus standard-dose vaccine 5

Safety Profile Remains Excellent

Large-scale surveillance (9,973,703 individuals) found no association with serious adverse events including 5:

• Guillain-Barré syndrome
• Febrile seizures (0-7 days post-vaccination)
• No new safety signals when co-administered with RSV or COVID-19 vaccines

Common Pitfalls to Avoid

1. Don't delay vaccination waiting for "better timing"—September/October is ideal, but vaccinate throughout the season as long as virus circulates 1

2. Don't dismiss vaccination due to lower VE this season—even 30-40% VE translates to substantial prevention of hospitalizations and deaths at the population level 2

3. Don't forget the two-dose requirement—children 6 months-8 years with inadequate prior vaccination history need 2 doses ≥4 weeks apart 1

4. Don't use multi-dose vials with thimerosal for children, pregnant women, or adults—this is now explicitly recommended against 1

Looking Ahead to 2026-27

No official data exists yet for the 2026-27 season. The WHO and FDA typically make strain selection decisions in February-March for the following Northern Hemisphere season. Current serological surveillance suggests continued antigenic drift in H3N2 subclade K variants may necessitate strain updates 3.